DeLong Mark Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Aug 13, 2024
Insider Transaction Report
Form 4
DeLong Mark Jeffrey
Chief Business & Strat Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-08-12−5,201→ 14,799 totalExercise: $13.85Exp: 2029-02-27→ Common Stock (5,201 underlying) - Exercise/Conversion
Common Stock
2024-08-12$13.85/sh+5,201$72,034→ 60,395 total
Footnotes (2)
- [F1]This includes 501 shares from 04/30/2024 ESPP purchase.
- [F2]This option was granted on February 8, 2019 and fully vested.